Cerus Corporation to Release First Quarter 2022 Financial Results on May 5, 2022

Rhea-AI Summary

Cerus Corporation (CERS) will release its first quarter 2022 financial results on May 5, 2022, post-market close. A conference call and webcast will occur at 4:30 P.M. ET to discuss the results and provide a business overview. The INTERCEPT Blood System, crucial for pathogen protection in blood components, is marketed globally, with the red blood cell system under regulatory review in Europe. The company aims to enhance blood safety and solidify its position as a global leader.

Positive

• The INTERCEPT Blood System is the only pathogen reduction system with both CE mark and FDA approval for platelets and plasma.
• The company is expanding its product offerings with the INTERCEPT red blood cell system under regulatory review in Europe.

Negative

• None.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on Cerus’ website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 8280547. The replay will be available approximately three hours after the call through May 19, 2022.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005008/en/

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When will Cerus Corporation announce its Q1 2022 results?

Cerus Corporation will announce its Q1 2022 financial results on May 5, 2022, after the market closes.

What time is the Cerus Corporation conference call for Q1 2022 results?

The conference call for Cerus Corporation's Q1 2022 results is scheduled for 4:30 P.M. ET on May 5, 2022.

How can I access the Cerus Corporation Q1 2022 financial results webcast?

You can access the Cerus Corporation Q1 2022 financial results webcast on the Investor Relations page of their website.

What products does Cerus Corporation offer?

Cerus Corporation offers the INTERCEPT Blood System for platelets, plasma, and cryoprecipitation, aimed at pathogen protection in blood supply.